Skip to Content

Sattva S. Neelapu, M.D.

Present Title & Affiliation

Primary Appointment

Deputy Department Chair ad interim, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Director of Laboratory and Translational Research, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Member, Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, The University of Texas Health Science Center, Houston, TX
Director, Lymphoma Tissue Bank, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1991 Jawaharlal Institute of Post-Graduate Medical Education and Research, Pondicherry, India, MBBS, Medicine

Postgraduate Training

7/2001-3/2004 Postdoctoral Fellowship, Tumor Immunology, National Cancer Institute, National Institutes of Health, Bethesda, MD
7/1998-6/2001 Clinical Fellowship, Medical Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD
7/1993-6/1995 Clinical Residency, Internal Medicine, Coney Island Hospital, Brooklyn, NY
7/1992-6/1993 Clinical Internship, Internal Medicine, Coney Island Hospital, Brooklyn, NY

Board Certifications

1995 American Board of Internal Medicine, Internal Medicine, Recertification Date: 2005
2000 American Board of Internal Medicine, Medical Oncology


Other Appointments/Responsibilities

Attending, Department of Internal Medicine, Coney Island Hospital, Brooklyn, NY, 7/1995-6/1998
Chief Resident, Department of Internal Medicine, Coney Island Hospital, Brooklyn, NY, 7/1994-6/1995

Honors and Awards

2015 Waun Ki Hong Award for Excellence in Team Science, Division of Cancer Medicine, UT MD Anderson Cancer Center
2014-2017 Faculty Scholar Award, UT MD Anderson Cancer Center
2014 Emil Frei, III Award for Excellence in Translational Research, Division of Cancer Medicine, UT MD Anderson Cancer Center
2010 LLS Translational Research Program Award, Leukemia and Lymphoma Society
2008 Clinical Scientist Development Award, Doris Duke Charitable Foundation
2007 ASH Scholar Award, American Society of Hematology
2006 ASCO Career Development Award, American Society of Clinical Oncology
2003 AACR Scholar-in-Training Award, American Association for Cancer Research 94th Annual Meeting, Washington, D.C.
2003 ASCO Merit Award, American Society of Clinical Oncology 39th Annual Meeting, Chicago, IL
2002 Fellows Award for Research Excellence, National Cancer Institute, National Institutes of Health, Bethesda, MD
2001 Senior Fellowship Training Award, National Cancer Institute, National Institutes of Health, Bethesda, MD
1995 Virginia Nash Award for outstanding professional performance as a Resident on the Medical Services, Coney Island Hospital, Brooklyn, NY
1993 Dr. Ghani Mohammad Memorial Award for outstanding professional performance as an Intern on the Medical Services, Coney Island Hospital, Brooklyn, NY

Selected Publications

Peer-Reviewed Original Research Articles

1. Li HS, Liu C, Xiao Y, Chu F, Liang X, Peng W, Hu J, Neelapu SS, Sun SC, Hwu P, Watowich SS. Bypassing STAT3-mediated Id2 inhibition improves the anti-tumor efficacy of dendritic cells. Science Signaling. In Press.
2. Weng J, Baio FE, Moriarty KE, Torikai H, Wang H, Liu Z, Maitri SN, Gwak D, Popescu MS, Cha SC, Neelapu SS, Kwak LW. Targeting B-cell malignancies through human B-cell receptor specific CD4 T cells. Oncoimmunology. In Press.
3. Pinnix CC, Osborne EM, Chihara D, Lai P, Zhou S, Ramirez MM, Oki Y, Hagemeister FB, Rodriguez AM, Samaniego F, Fowler N, Romaguera JE, Turturro F, Fayad L, Westin JR, Nastoupil L, Neelapu SS, Cheah CY, Dabaja BS, Milgrom SA, Smith GL, Horace P, Milbourne A, Wogan CF, Ballas L, Fanale MA. Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. JAMA Oncol 2(8):1065-9, 8/2016. e-Pub 5/2016. PMID: 27227654.
4. Chihara D, Westin JR, Miranda RN, Cheah CY, Oki Y, Turturro F, Romaguera JE, Neelapu SS, Nastoupil LJ, Fayad LE, Rodriguez MA, Fowler NH, Orlowski RZ, Wang M, Hagemeister FB, Medeiros LJ, Fanale MA. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. Br J Haematol. e-Pub 7/2016. PMID: 27378601.
5. Anderlini P, Saliba RM, Ledesma C, Plair T, Alousi AM, Hosing CM, Khouri IF, Nieto Y, Popat UR, Shpall EJ, Fanale MA, Hagemeister FB, Oki Y, Neelapu S, Romaguera JE, Younes A, Champlin RE. Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. Biol Blood Marrow Transplant 22(7):1333-7, 7/2016. e-Pub 4/2016. PMID: 27064056.
6. Cheah CY, Chihara D, Horowitz S, Sevin A, Oki Y, Zhou S, Fowler NH, Romaguera JE, Turturro F, Hagemeister FB, Fayad LE, Wang M, Neelapu SS, Nastoupil LJ, Westin JR, Rodriguez MA, Samaniego F, Anderlini P, Nieto Y, Fanale MA. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol 27(7):1317-23, 7/2016. e-Pub 4/2016. PMID: 27091808.
7. Chen Y, Neelapu S, Feng L, Bi W, Yang TH, Wang M, Fanale MA, Westin JR, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Fowler NH, McLaughlin P, Cabanillas F, Oki Y, Nastoupil LJ, Rodriguez A. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. Br J Haematol. e-Pub 7/2016. PMID: 27448187.
8. Yang Q, Chen LS, Ha MJ, Do KA, Neelapu SS, Gandhi V. Idelalisib impacts cell growth through inhibiting translation regulatory mechanisms in mantle cell lymphoma. Clin Cancer Res. e-Pub 6/2016. PMID: 27342398.
9. Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer. e-Pub 6/2016. PMID: 27351173.
10. Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, Hagemeister FB, Fayad LE, Westin JR, Oki Y, Fanale MA, Romaguera JE, Wang ML, Lee H, Turturro F, Samaniego F, Rodriguez MA, Neelapu SS, Fowler NH. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol 27(5):895-901, 5/2016. e-Pub 1/2016. PMID: 26802151.
11. Fowler NH, Cheah CY, Gascoyne RD, Gribben J, Neelapu SS, Ghia P, Bollard C, Ansell S, Curran M, Wilson WH, O'Brien S, Grant C, Little R, Zenz T, Nastoupil LJ, Dunleavy K. Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica 101(5):531-40, 5/2016. PMCID: PMC5004369.
12. Younes A, Berdeja JG, Patel MR, Flinn I, Gerecitano JF, Neelapu SS, Kelly KR, Copeland AR, Akins A, Clancy MS, Gong L, Wang J, Ma A, Viner JL, Oki Y. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. Lancet Oncol 17(5):622-31, 5/2016. e-Pub 3/2016. PMID: 27049457.
13. Zhang H, Chen Z, Neelapu SS, Romaguera J, McCarty N. Hedgehog inhibitors selectively target cell migration and adhesion of mantle cell lymphoma in bone marrow microenvironment. Oncotarget 7(12):14350-65, 3/2016. e-Pub 2/2016. PMCID: PMC4924720.
14. Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen JE, Wang Z, Ma W, Lee HC, Orlowski R, Sarbassov dos D, Lorenzi PL, Huang X, Neelapu SS, McDonnell T, Miranda RN, Wang M, Kantarjian H, Konopleva M, Davis RE, Andreeff M. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Sci Signal 9(415):ra17, 2/2016. e-Pub 2/2016. PMCID: PMC4815038.
15. Sarkar A, Balakrishnan K, Chen J, Patel V, Neelapu SS, McMurray JS, Gandhi V. Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma. Oncotarget 7(3):3461-76, 1/2016. e-Pub 12/2015. PMCID: PMC4823120.
16. Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O'Brien S, Davis RE, Burger JA. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. Br J Haematol 171(5):726-35, 12/2015. e-Pub 9/2015. PMCID: PMC4715651.
17. Cheah CY, Nastoupil LJ, McLaughlin P, Fanale MA, Neelapu SS, Fayad LE, Hagemeister FB, Fowler NH. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity. Br J Haematol. e-Pub 12/2015. PMID: 26683805.
18. Fowler NH, Nastoupil LJ, Hagemeister FB, Neelapu SS, Fayad LE, LeBlanc D, Samaniego F, Cheah CY. Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma. Haematologica 100(11):e454-7, 11/2015. e-Pub 8/2015. PMID: 26250576.
19. Oki Y, Fanale M, Romaguera J, Fayad L, Fowler N, Copeland A, Samaniego F, Kwak LW, Neelapu S, Wang M, Feng L, Younes A. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. Br J Haematol 171(4):463-70, 11/2015. e-Pub 7/27/2015. PMID: 26213141.
20. Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol 171(4):509-16, 11/2015. e-Pub 8/10/2015. PMID: 26260306.
21. Oki Y, Neelapu SS, Fanale M, Kwak LW, Fayad L, Rodriguez MA, Wallace M, Klinger M, Carlton V, Kong K, Faham M, Younes A. Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach. Br J Haematol 169(5):689-93, 6/2015. e-Pub 3/2015. PMID: 25818067.
22. Samaniego F, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Berkova Z, Khashab T, Sehgal L, Vega-Vasquez F, Kwak LW. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. Br J Haematol 169(6):814-23, 6/2015. e-Pub 3/2015. PMID: 25828695.
23. Cheah CY, Nastoupil LJ, Neelapu SS, Forbes SG, Oki Y, Fowler NH. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood 125(21):3357-9, 5/2015. PMID: 25999447.
24. Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, Rodriguez MA, Fayad L, Hagemeister FB, Nastoupil L, Turturro F, Fowler N, Fanale MA, Nieto Y, Khouri IF, Ahmed S, Medeiros LJ, Davis RE, Westin J. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by (18)fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys 92(1):113-21, 5/2015. PMCID: PMC4418191.
25. Oki Y, Ewer MS, Lenihan DJ, Fisch MJ, Hagemeister FB, Fanale M, Romaguera J, Pro B, Fowler N, Younes A, Astrow AB, Huang X, Kwak LW, Samaniego F, McLaughlin P, Neelapu SS, Wang M, Fayad LE, Durand JB, Rodriguez MA. Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Label, Single Arm, Phase II Trial. Clin Lymphoma Myeloma Leuk 15(3):152-8, 3/2015. e-Pub 9/2014. PMCID: PMC4344896.
26. Mathur R, Sehgal L, Braun FK, Berkova Z, Romaguerra J, Wang M, Rodriguez MA, Fayad L, Neelapu SS, Samaniego F. Targeting Wnt pathway in mantle cell lymphoma-initiating cells. J Hematol Oncol 8(1):63, 2015. e-Pub 6/2015. PMCID: PMC4460883.
27. Sehgal L, Mathur R, Braun FK, Wise JF, Berkova Z, Neelapu S, Kwak LW, Samaniego F. FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma. Leukemia 28(12):2376-87, 12/2014. e-Pub 4/2014. PMID: 24811343.
28. Voo KS, Foglietta M, Percivalle E, Chu F, Nattamai D, Harline M, Lee ST, Bover L, Lin HY, Baladandayuthapani V, Delgado D, Luong A, Davis RE, Kwak LW, Liu YJ, Neelapu SS. Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. Int J Cancer 135(12):2834-46, 12/2014. e-Pub 5/2014. PMID: 24771328.
29. Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 15(12):1311-8, 11/2014. e-Pub 10/2014. PMID: 25439689.
30. Samaniego F, Berkova Z, Romaguera JE, Fowler N, Fanale MA, Pro B, Shah JJ, McLaughlin P, Sehgal L, Selvaraj V, Braun FK, Mathur R, Feng L, Neelapu SS, Kwak LW. (90) Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease. Br J Haematol 167(2):207-13, 10/2014. e-Pub 7/8/2014. PMID: 25040450.
31. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 166(6):891-901, 9/2014. e-Pub 6/18/2014. PMID: 24943107.
32. Yoshimura M, Ishizawa J, Ruvolo V, Dilip A, Quintás-Cardama A, McDonnell TJ, Neelapu SS, Kwak LW, Shacham S, Kauffman M, Tabe Y, Yokoo M, Kimura S, Andreeff M, Kojima K. Induction of p53-mediated transcription and apoptosis by Exportin-1 (XPO1) inhibition in mantle cell lymphoma. Cancer Sci 105(7):795-801, 7/2014. e-Pub 6/3/2014. PMCID: PMC4106990.
33. Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez MA, Neelapu S, Samaniego F, Kwak L, Younes A. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol 165(1):112-6, 4/2014. e-Pub 1/2014. PMID: 24386943.
34. Liu X, Chen X, Zhong B, Wang A, Wang X, Chu F, Nurieva RI, Yan X, Chen P, van der Flier LG, Nakatsukasa H, Neelapu SS, Chen W, Clevers H, Tian Q, Qi H, Wei L, Dong C. Transcription factor achaete-scute homologue 2 initiates follicular T-helper-cell development. Nature 507(7493):513-8, 3/2014. e-Pub 1/2014. PMCID: PMC4012617.
35. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15(1):69-77, 1/2014. e-Pub 12/2013. PMID: 24332512.
36. Oki Y, Buglio D, Fanale M, Fayad L, Copeland A, Romaguera J, Kwak LW, Pro B, de Castro Faria S, Neelapu S, Fowler N, Hagemeister F, Zhang J, Zhou S, Feng L, Younes A. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res 19(24):6882-90, 12/15/2013. e-Pub 10/4/2013. PMID: 24097867.
37. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol 163(5):611-20, 12/2013. e-Pub 10/1/2013. PMID: 24117234.
38. Armand P, Oki Y, Neuberg DS, Faham M, Cummings C, Klinger M, Weng L, Bhattar S, Lacasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Fowler NH, Alma Rodriguez M, Wallace MJ, Neelapu SS, Rodig S, Younes A, Freedman AS. Detection of circulating tumour DNA in patients with aggressive B-cell Non-Hodgkin lymphoma. Br J Haematol 163(1):123-6, 10/2013. e-Pub 6/2013. PMID: 23795711.
39. Yang Q, Chen LS, Neelapu SS, Gandhi V. Combination of Pim Kinase Inhibitor SGI-1776 and Bendamustine in B-Cell Lymphoma. Clin Lymphoma Myeloma Leuk 13 Suppl 2:S355-62, 9/2013. PMID: 24290221.
40. Wang L, Qian J, Lu Y, Li H, Bao H, He D, Liu Z, Zheng Y, He J, Li Y, Neelapu S, Yang J, Kwak LW, Yi Q, Cai Z. Immune evasion evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells. Haematologica 98(9):1458-66, 9/2013. e-Pub 3/2013. PMCID: PMC3762104.
41. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 27(9):1902-9, 9/2013. e-Pub 4/2013. PMID: 23545991.
42. Rawal S, Chu F, Zhang M, Park HJ, Nattamai D, Kannan S, Sharma R, Delgado D, Chou T, Lin HY, Baladandayuthapani V, Luong A, Vega F, Fowler N, Dong C, Davis RE, Neelapu SS. Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment. J Immunol 190(12):6681-93, 6/2013. e-Pub 5/2013. PMCID: PMC3680117.
43. Cha SC, Qin H, Kannan S, Rawal S, Watkins LS, Baio FE, Wu W, Ong J, Wei J, Kwak B, Kim S, Popescu MS, Paick DS, Kim K, Luong A, Davis RE, Schroeder HW, Kwak LW, Neelapu SS. Nonstereotyped lymphoma B cell receptors recognize vimentin as a shared autoantigen. J Immunol 190(9):4887-98, 5/2013. e-Pub 3/2013. PMCID: PMC3633696.
44. Westin JR, Thompson MA, Cataldo VD, Fayad LE, Fowler N, Fanale MA, Neelapu S, Samaniego F, Romaguera J, Shah J, McLaughlin P, Pro B, Kwak LW, Sanjorjo P, Murphy WA, Jimenez C, Toth B, Dong W, Hagemeister FB. Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial. Clin Lymphoma Myeloma Leuk 13(2):99-105, 4/2013. e-Pub 12/2012. PMID: 23276888.
45. Foglietta M,* Neelapu SS,* (*co-first authors), Kwak LW, Jiang Y, Nattamai D, Lee ST, Fowler DH, Sportes C, Gress RE, Steinberg SM, Vence LM, Radvanyi L, Dwyer KC, Qazilbash MH, Bryant RN, Bishop MR. Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients. Bone Marrow Transplant 48(2):269-77, 2/2013. e-Pub 7/2012. PMCID: PMC3469751.
46. Chen Z, Pittman EF, Romaguera J, Fayad L, Wang M, Neelapu SS, McLaughlin P, Kwak L, McCarty N. Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma. PLoS One 8(8):e69126, 2013. e-Pub 8/2013. PMCID: PMC3732253.
47. Younes A, Romaguera J, Fanale M, McLaughlin P, Hagemeister F, Copeland A, Neelapu S, Kwak L, Shah J, de Castro Faria S, Hart S, Wood J, Jayaraman R, Ethirajulu K, Zhu J. Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes. J Clin Oncol 30(33):4161-7, 11/2012. e-Pub 9/2012. PMID: 22965964.
48. Yang Q, Chen LS, Neelapu SS, Miranda RN, Medeiros LJ, Gandhi V. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma. Blood 120(17):3491-500, 10/2012. e-Pub 9/2012. PMCID: PMC3482859.
49. Younes A, Kim S, Romaguera J, Copeland A, Farial Sde C, Kwak LW, Fayad L, Hagemeister F, Fanale M, Neelapu S, Lambert JM, Morariu-Zamfir R, Payrard S, Gordon LI. Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma. J Clin Oncol 30(22):2776-82, 8/1/2012. e-Pub 7/2/2012. PMID: 22753910.
50. Weng J, Rawal S, Chu F, Park HJ, Sharma R, Delgado DA, Fayad L, Fanale M, Romaguera J, Luong A, Kwak LW, Neelapu SS. TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas. Blood 120(8):1613-23, 8/23/2012. e-Pub 5/29/2012. PMCID: PMC3429305.
51. Buglio D, Palakurthi S, Byth K, Vega F, Toader D, Saeh J, Neelapu SS, Younes A. Essential role of TAK1 in regulating mantle cell lymphoma survival. Blood 120(2):347-55, 7/12/2012. e-Pub 5/30/2012. PMCID: PMC3460632.
52. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 13(7):716-23, 7/2012. e-Pub 6/6/2012. PMID: 22677155.
53. Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood 119(26):6373-8, 6/28/2012. e-Pub 5/14/2012. PMID: 22586182.
54. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase II study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood 119(18):4123-8, 5/3/2012. e-Pub 2/27/2012. PMCID: PMC3359733.
55. Wang W, Corrigan-Cummins M, Hudson J, Maric I, Simakova O, Neelapu SS, Kwak LW, Janik JE, Gause B, Jaffe ES, Calvo KR. MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response. Haematologica 97(4):586-94, 4/2012. e-Pub 11/18/2011. PMCID: PMC3347661.
56. Qian J, Zheng Y, Zheng C, Wang L, Qin H, Hong S, Li H, Lu Y, He J, Yang J, Neelapu S, Kwak LW, Hou J, Yi Q. Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma. Blood 119(1):161-9, 1/5/2012. e-Pub 11/2/2011. PMCID: PMC3251227.
57. Westin JR, Gibbs A, Mills KR, Neelapu SS. Hodgkin lymphoma untreated for six years presenting with tracheoesophageal fistula. Case Report Med 2012:457908, 2012. e-Pub 7/2012. PMCID: PMC3395413.
58. Westin JR, Neelapu SS. Therapy of newly diagnosed follicular lymphoma. Front Oncol 2:188, 2012. e-Pub 12/2012. PMCID: PMC3518764.
59. Singh RR, Kunkalla K, Qu C, Schlette E, Neelapu SS, Samaniego F, Vega F. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene 30(49):1-13, 12/8/2011. e-Pub 5/30/2011. PMCID: PMC3165099.
60. Younes A, Oki Y, Bociek RG, Kuruvilla J, Fanale M, Neelapu S, Copeland A, Buglio D, Galal A, Besterman J, Li Z, Drouin M, Patterson T, Ward MR, Paulus JK, Ji Y, Medeiros LJ, Martell RE. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol 12(13):1222-8, 12/2011. e-Pub 10/25/2011. PMID: 22033282.
61. Jones RJ, Baladandayuthapani V, Neelapu S, Fayad LE, Romaguera JE, Wang M, Sharma R, Yang D, Orlowski RZ. HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma. Blood 118(15):4140-9, 10/13/2011. e-Pub 8/15/2011. PMCID: PMC3204731.
62. Weng J, Cha SC, Matsueda S, Alatrash G, Popescu MS, Yi Q, Molldrem JJ, Wang M, Neelapu SS, Kwak LW. Targeting human B-cell malignancies through Ig light chain specific cytotoxic T lymphocytes. Clin Cancer Res 17(18):5945-52, 9/15/2011. e-Pub 8/3/2011. PMCID: PMC3176952.
63. Chung Y, Tanaka S, Chu F, Nurieva RI, Martinez GJ, Rawal S, Wang YH, Lim H, Reynolds JM, Zhou XH, Fan HM, Liu ZM, Neelapu SS, Dong C. Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nat Med 17(8):983-8, 8/2011. e-Pub 7/24/2011. PMCID: PMC3151340.
64. Schuster SJ,* Neelapu SS,* (*co-first authors) Gause BL, Janik JE, Muggia FM, Gockerman JP, Winter JN, Flowers CR, Nikcevich DA, Sotomayor EM, McGaughey DS, Jaffe ES, Chong EA, Reynolds CW, Berry DA, Santos CF, Popa MA, McCord AM, Kwak LW. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 29(20):2787-94, 7/2011. e-Pub 5/2011. PMCID: PMC3139394.
65. Jamshed S, Fowler DH, Neelapu SS, Dean RM, Steinberg SM, Odom J, Bryant K, Hakim F, Bishop MR. EPOCH-F: a novel salvage regimen for multiple myeloma prior to reduced-intensity allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 46(5):676-81, 5/2011. e-Pub 7/26/2010. PMID: 20661232.
66. Park HJ, Qin H, Cha SC, Sharma R, Chung Y, Schluns KS, Neelapu SS, Overwijk WW, Hwu P, Kwak LW. Induction of TLR4-dependent CD8+ T cell immunity by murine ß-defensin2 fusion protein vaccines. Vaccine 29(18):3476-82, 4/18/2011. e-Pub 3/5/2011. PMID: 21382485.
67. Weng J, Neelapu SS, Woo AF, Kwak LW. Identification of Human Idiotype-Specific T Cells in Lymphoma and Myeloma. Curr Top Microbiol Immunol 344:193-210, 2011. e-Pub 6/2010. PMID: 20549471.
68. Dennison JB, Shanmugam M, Ayres ML, Qian J, Krett NL, Medeiros LJ, Neelapu SS, Rosen ST, Gandhi V. 8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma. Blood 116(25):5622-30, 12/16/2010. e-Pub 9/15/2010. PMID: 20844237.
69. Qin H, Cha SC, Neelapu SS, Liu C, Wang YH, Wei J, Qin XF, Liu YJ, Kwak LW. Generation of an immune microenvironment as a novel mechanism for myotoxins to potentiate genetic vaccines. Vaccine 28(50):7970-8, 11/2010. PMID: 20937320.
70. Chen Z, Ayala P, Wang M, Fayad L, Katz RL, Romaguera J, Caraway N, Neelapu SS, Kwak LW, Simmons PJ, McCarty N. Prospective isolation of clonogenic mantle cell lymphoma-initiating cells. Stem Cell Res 5(3):212-25, 11/2010. e-Pub 8/6/2010. PMCID: PMC2952723.
71. Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, McLaughlin P, Hagemeister F, Neelapu S, Copeland A, Samuels BI, Loyer EM, Ji Y, Younes A. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 27(31):5213-8, 11/1/2009. e-Pub 9/21/2009. PMID: 19770379.
72. Gloghini A, Buglio D, Khaskhely NM, Georgakis G, Orlowski RZ, Neelapu SS, Carbone A, Younes A. Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. Br J Haematol 147(4):515-25, 11/2009. e-Pub 9/22/2009. PMID: 19775297.
73. Qin H, Cha SC, Neelapu SS, Lou Y, Wei J, Liu YJ, Kwak LW. Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity. Blood 114(19):4142-9, 11/2009. e-Pub 9/2009. PMID: 19749091.
74. Freedman A, Neelapu SS, Nichols C, Robertson MJ, Djulbegovic B, Winter JN, Bender JF, Gold DP, Ghalie RG, Stewart ME, Esquibel V, Hamlin P. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol 27(18):3036-43, 6/2009. e-Pub 5/2009. PMID: 19414675.
75. Esmaeli B, McLaughlin P, Pro B, Samaniego F, Gayed I, Hagemeister F, Romaguera J, Cabanillas F, Neelapu SS, Banay R, Fayad L, Wayne Saville M, Kwak LW. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann Oncol 20(4):709-14, 4/2009. e-Pub 1/15/2009. PMID: 19150940.
76. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111(12):5530-6, 6/15/2008. e-Pub 4/14/2008. PMID: 18411419.
77. Park HJ, Neelapu SS. Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials. Br J Haematol 142(2):179-91, 6/2008. e-Pub 4/2008. PMCID: PMC2744838.
78. Oki Y, Pro B, Fayad LE, Romaguera J, Samaniego F, Hagemeister F, Neelapu S, McLaughlin P, Goy A, Younes A. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 112(4):831-6, 2/15/2008. PMID: 18085611.
79. Lee ST, Liu S, Radvanyi L, Sukhumalchandra P, Molldrem JJ, Wieder ED, Hwu P, Liu YJ, Kwak LW, Lizée G, Neelapu SS. A novel strategy for rapid and efficient isolation of human tumor-specific CD4(+) and CD8(+) T-cell clones. J Immunol Methods 331(1-2):13-26, 2/2008. e-Pub 10/2007. PMCID: PMC2265521.
80. Zhu K, Qin H, Cha SC, Neelapu SS, Overwijk W, Lizee GA, Abbruzzese JL, Hwu P, Radvanyi L, Kwak LW, Chang DZ. Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. Vaccine 25(46):7955-61, 11/14/2007. e-Pub 9/14/2007. PMID: 17933439.
81. Dang NH, Fayad L, McLaughlin P, Romaguara JE, Hagemeister F, Goy A, Neelapu S, Samaniego F, Walker PL, Wang M, Rodriguez MA, Tong AT, Pro B. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. Br J Haematol 138(4):502-5, 8/2007. e-Pub 6/29/2007. PMID: 17608763.
82. Popescu MC, Robb RJ, Batenjany MM, Boni LT, Neville ME, Pennington RW, Neelapu SS, Kwak LW. A novel proteoliposomal vaccine elicits potent antitumor immunity in mice. Blood 109(12):5407-10, 6/15/2007. e-Pub 3/9/2007. PMCID: PMC1890838.
83. Neelapu SS, Gause BL, Harvey L, Lee ST, Frye AR, Horton J, Robb RJ, Popescu MC, Kwak LW. A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma. Blood 109(12):5160-3, 6/2007. e-Pub 3/2007. PMCID: PMC1941785.
84. O'Mahony D, Morris JC, Quinn C, Gao W, Wilson WH, Gause B, Pittaluga S, Neelapu S, Brown M, Fleisher TA, Gulley JL, Schlom J, Nussenblatt R, Albert P, Davis TA, Lowy I, Petrus M, Waldmann TA, Janik JE. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res 13(3):958-64, 2/1/2007. PMID: 17289891.
85. Lee ST, Jiang YF, Park KU, Woo AF, Neelapu SS. BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma. Expert Opin Biol Ther 7(1):113-22, 1/2007. PMID: 17150023.
86. Pai Kasturi S, Qin H, Thomson KS, El-Bereir S, Cha SC, Neelapu S, Kwak LW, Roy K. Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles. J Control Release 113(3):261-70, 7/20/2006. e-Pub 5/3/2006. PMID: 16793161.
87. Neelapu SS, Lee ST, Qin H, Cha SC, Woo AF, Kwak LW. Therapeutic lymphoma vaccines: importance of T-cell immunity. Expert Rev Vaccines 5(3):381-94, 6/2006. PMID: 16827622.
88. Cha SC, Kwak LW, Ruffini PA, Qin H, Neelapu S, Biragyn A. Cloning of B cell lymphoma-associated antigens using modified phage-displayed expression cDNA library and immunized patient sera. J Immunol Methods 312(1-2):79-93, 5/30/2006. e-Pub 3/31/2006. PMCID: PMC2431127.
89. Neelapu SS, Kwak LW, Kobrin CB, Reynolds CW, Janik JE, Dunleavy K, White T, Harvey L, Pennington R, Stetler-Stevenson M, Jaffe ES, Steinberg SM, Gress R, Hakim F, Wilson WH. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med 11(9):986-91, 9/2005. e-Pub 8/2005. PMID: 16116429.
90. Neelapu SS, Munshi NC, Jagannath S, Watson TM, Pennington R, Reynolds C, Barlogie B, Kwak LW. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma. Bone Marrow Transplant 36(4):315-23, 8/2005. PMID: 15968284.
91. Neelapu SS, Baskar S, Gause BL, Kobrin CB, Watson TM, Frye AR, Pennington R, Harvey L, Jaffe ES, Robb RJ, Popescu MC, Kwak LW. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen. Clin Cancer Res 10(24):8309-17, 12/2004. PMID: 15623607.
92. Biragyn A, Ruffini PA, Coscia M, Harvey LK, Neelapu SS, Baskar S, Wang JM, Kwak LW. Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo. Blood 104(7):1961-9, 10/1/2004. e-Pub 6/10/2004. PMID: 15191951.
93. Malyguine A, Strobl SL, Shafer-Weaver KA, Ulderich T, Troke A, Baseler M, Kwak LW, Neelapu SS. A modified human ELISPOT assay to detect specific responses to primary tumor cell targets. J Transl Med 2(1):9, 3/29/2004. PMCID: PMC415560.
94. Kwak LW, Neelapu SS, Bishop MR. Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion. Semin Oncol 31(1):37-46, 2/2004. PMID: 14970936.
95. Neelapu S, Figg WD, Dahut W, Reed E. Leptomeningeal carcinomatosis in metastatic prostate cancer. South Med J 95(1):107-8, 1/2002. PMID: 11827241.
96. Neelapu SS, Baskar S, Kwak LW. Detection of keyhole limpet hemocyanin (KLH)-specific immune responses by intracellular cytokine assay in patients vaccinated with idiotype-KLH vaccine. J Cancer Res Clin Oncol 127 Suppl 2:R14-9, 10/2001. PMID: 11768619.

Invited Articles

1. Sathyanarayanan V, Neelapu SS. Cancer immunotherapy: Strategies for personalization and combinatorial approaches. Mol Oncol 9(10):2043-53, 12/2015. e-Pub 10/2015. PMCID: PMC4684975.
2. Cheah CY, Fowler NH, Neelapu SS. Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma. Curr Opin Oncol 27(5):384-91, 9/2015. PMID: 26248256.
3. Nastoupil LJ, Neelapu SS. Novel immunologic approaches in lymphoma: unleashing the brakes on the immune system. Curr Oncol Rep 17(7):30, 7/2015. PMID: 25986722.
4. Chu F, Neelapu SS. Anti-PD-1 antibodies for the treatment of B-cell lymphoma: Importance of PD-1(+) T-cell subsets. Oncoimmunology 3(1):e28101, 1/2014. e-Pub 2/2014. PMCID: PMC4011813.
5. Kannan S, Neelapu SS. Vaccination strategies in follicular lymphoma. Curr Hematol Malig Rep 4(4):189-95, 10/2009. PMID: 20425407.
6. Neelapu SS. Choosing treatment options in newly diagnosed patients with multiple myeloma. Community Oncology 6(2):55-58, 2/2009.
7. Foglietta M, Neelapu SS, Kwak LW. Therapeutic Vaccines for lymphoma: From bench to beside. American Society of Clinical Oncology Education Book, 2009.
8. Neelapu SS. Kwak LW. Translational development of therapeutic vaccines for lymphomas. American Society of Clinical Oncology Education Book:736-740, 6/2007.
9. Lee ST, Neelapu SS, Kwak LW. Therapeutic vaccine for lymphoma. Yonsei Med J 48(1):1-10, 2/2007. PMCID: PMC2628002.
10. Neelapu SS, Kwak LW. Vaccine therapy for B-cell lymphomas: next-generation strategies. Hematology Am Soc Hematol Educ Program:243-9, 2007. PMID: 18024636.
11. Ruffini PA, Neelapu SS, Kwak LW, Biragyn A. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Haematologica 87(9):989-1001, 9/2002. PMID: 12217812.


1. Neelapu SS, Sharma P. Targeting the tumor niche to treat cancer. Proc Natl Acad Sci U S A 112(42):12907-8, 10/2015. e-Pub 10/2015. PMCID: PMC4620886.
2. Neelapu SS. Mutations and microenvironment collude in FL. Blood 125(4):587-9, 1/2015. PMID: 25614636.
3. Neelapu SS, Kwak LW. Rush hour traffic: directing T cells to tumor. J Natl Cancer Inst 106(11), 11/2014. e-Pub 9/24/2014. PMID: 25255804.
4. Neelapu SS, Kwak LW. Cancer vaccines: up, down.. up again? Blood 113(1):1-2, 1/2009. PMID: 19122114.

Book Chapters

1. Kassim AA, Neelapu SS, Kwak LW, Kaer LV. Immunotherapy. In: Wintrobe’s Clinical Hematology, 13th Edition, 2013.
2. Neelapu SS. Indolent B-Cell Non-Hodgkin Lymphomas. In: Sixty Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center, 2013.
3. Neelapu SS, Dunbar CE. Multiple Myeloma. In: Bethesda Handbook of Clinical Oncology, 3rd edition, 2010.
4. Neelapu SS, Kwak LW. Principles of Vaccine Therapy. In: William’s Hematology, 8th edition, 2010.
5. Qin H, Neelapu SS, Cha SC, Kwak LW. Vaccine Therapies. In: The Lymphoid Neoplasms, 3rd edition. Ed(s) I Magrath. Edward Arnold Company, 2010.
6. Kassim AA, Neelapu SS, Kwak LW, Van Kaer L. Immunotherapy. In: Wintrobe's Clinical Hematology, 12th edition, 2008.
7. Neelapu SS, Dunbar CE. Multiple Myeloma. In: Bethesda Handbook of Clinical Oncology, 2nd edition, 2005.
8. Neelapu SS, Kwak LW. Vaccine Approaches to non-hodgkin’s lymphoma therapy, Malignant Lymphomas. In: American Cancer Society Atlas of Clinical Oncology, 2002.
9. Neelapu SS, Dahut W. Bladder cancer. In: Bethesda Handbook of Clinical Oncology, 1st edition, 2000.

Last updated: 9/5/2016